However, to limit these adverse events, one must pay attention to each HSP90 inhibitor’s selectivity towards normal cells, as AUY922 does not preferentially impair the proliferation of cancer cells over normal cells, whereas the C-terminal Hsp90 modulator SM258 only impacts colon cancer cell lines [162]. The gene discussed is HSP90AA1; the disease is malignant colon neoplasm.